본문 바로가기 대메뉴 바로가기
박경찬 교수

Park Kyung Chan

INFO

  • 소속캠퍼스한국생명공학연구원 스쿨
  • 전공 생명과학
    (기능유전체학)
  • 연락처042-879-8115
  • 출신전공분자생물학과
  • 학위박사
  • 최종출신대학서울대학교
  • 이메일

연구분야

암생물학

Cancer Biology

대표연구실적

-  DC Lee, HA Sohn, Z-Y Park, S Oh, Y K Kang, K-M Lee, M Kang, Y J Jang, S-J Yang, YK Hong, H Noh, J-A Kim, DJ Kim, K-H Bae, DM Kim, SJ Chung, HS Yoo, D-Y Yu, KC Park (Corresponding), YI Yeom. NDRG3-Mediated Lactate Signaling in Hypoxia. Cell. 2015.04.23 -  Park YS, Kim DJ, Koo H, Jang SH, You Y-M, Cho JH, Yang S-J, Yu ES, Jung Y, Lee DC, Kim J-A, Park Z-Y, Park KC (Corresponding), Yeom YI. AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth. In Press. -  Park KC, Yeom YI, Kim TW, Park Z-Y, Kang YK, Yang S-J, Choi, B-J, Lee DC, Shon HA, Yoo HS. Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer. Patent No.: US880****, Date of Patent: Aug. 19, 2014

논문(최근 5년)

-  A lactate-induced response to hypoxia[ CELL,2015-04-23] -  Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.[ EXPERIMENTAL CELL RESEARCH,2015-08-01] -  AKT-induced PKM2 phosphorylation signals for IGF-1-stimulated cancer cell growth[Oncotarget,2016-06-04] -  NDRG3-mediated lactate signaling in hypoxia[BMB REPORTS,2015-06-01] -  A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia[ MOLECULES AND CELLS,2015-03-26] -  Chitosan-mediated non-viral gene delivery with improved serum stability and reduced cytotoxicity[BIOTECHNOLOGY AND BIOPROCESS ENGINEERING,2014-08-12] -  SH3RF2 functions as an oncogene by mediating PAK4 protein stability.[ CARCINOGENESIS,2014-03-01] -  Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1α protein stability.[EMBO JOURNAL,2017-04-13] -  RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation[CELL DEATH & DISEASE,2018-05-22] -  RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.[CELL DEATH & DISEASE,2018-05-22]

특허(최근 5년)

-  Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single CpG site in TTP promoter and treatment of cancers by regulating its epigenetic status[2015-01-01] -  Composition containing inhibitors of the expression or activity of SH3RF2 for preventing or treating cancer[2015-01-01] -  NDRG3 단백질 특이적인 항체 및 이의 용도[2015-01-01] -  피루브산 키나아제 엠투(Pyruvate kinase type M2, PKM2)의발현또는활성억제제를유효성분으로함유하는 항암제민감성증진용약학적조성물[2015-01-01]

연구과제 수행 실적

다중유전체 분석을 통한 비흡연폐암의 신규치료타겟 발굴 및 기전규명 유전체 빅데이터 기반 난치성 질환 맞춤치료 원천기술 개발사업 젖산신호 조절 신규 암유전자 NDRG3에 의한 염증질환 조절기전 연구 표현형분석 기반 고기능성 유용유전자 고속발굴시스템 구축 및 활용